Aclaris Therapeutics Q1 2025 10-Q Filing
Ticker: ACRS · Form: 10-Q · Filed: May 8, 2025 · CIK: 1557746
| Field | Detail |
|---|---|
| Company | Aclaris Therapeutics, INC. (ACRS) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Aclaris Therapeutics filed its Q1 2025 10-Q, showing key financial figures like common stock and retained earnings.
AI Summary
Aclaris Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company, incorporated in Delaware and headquartered in Wayne, PA, operates in the pharmaceutical preparations sector. Key financial data points such as common stock, retained earnings, and additional paid-in capital are reported for various periods, including Q1 2025.
Why It Matters
This filing provides investors with an update on Aclaris Therapeutics' financial position and operational performance for the first quarter of 2025, crucial for assessing the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing with no immediate red flags or significant new risks disclosed.
Key Numbers
- Q1 2025 — Reporting Period (First quarter of fiscal year 2025)
- March 31, 2025 — As of Date (End date for financial reporting)
Key Players & Entities
- Aclaris Therapeutics, Inc. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- 20250508 (date) — Filing date of the report
- Wayne, PA (location) — Company headquarters location
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What were the key financial statement line items reported for the period ending March 31, 2025?
The filing references us-gaap:CommonStockMember, us-gaap:RetainedEarningsMember, us-gaap:AdditionalPaidInCapitalMember, and us-gaap:AccumulatedOtherComprehensiveIncomeMember for periods including March 31, 2025.
When was this 10-Q report filed with the SEC?
This 10-Q report was filed on May 8, 2025.
What is Aclaris Therapeutics, Inc.'s Standard Industrial Classification code?
Aclaris Therapeutics, Inc. is classified under code 2834, which corresponds to Pharmaceutical Preparations.
What is the fiscal year end for Aclaris Therapeutics, Inc.?
The company's fiscal year ends on December 31.
Where is Aclaris Therapeutics, Inc. headquartered?
Aclaris Therapeutics, Inc. is headquartered in Wayne, Pennsylvania.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Aclaris Therapeutics, Inc. (ACRS).